Zymeworks Inc. ZYME
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · Canada · zymeworks.com
Vancouver-based biotechnology company managing licensed assets, including Ziihera (zanidatamab) royalties, while developing multifunctional antibody therapeutics; currently acquiring Theravance Biopharma.
Key ratios
FreeCashFlowOnSale 2025 -0.33
FreeCashFlowOnSale 2024 -1.47
FreeCashFlowOnSale 2023 -1.59
NetIncomeMargin TTM -1.26
NetIncomeMargin 2025 -0.77
NetIncomeMargin 2024 -1.61
NetIncomeMargin 2023 -1.56
ReturnOnAssets TTM -0.16
ReturnOnAssets 2025 -0.14
ReturnOnAssets 2024 -0.15
ReturnOnAssets 2023 -0.14
ReturnOnEquity TTM -0.42
ReturnOnEquity 2025 -0.27
ReturnOnEquity 2024 -0.31
ReturnOnEquity 2023 -0.25
TotalRevenueYoYGrowth 2025 0.39
TotalRevenueYoYGrowth 2024 0
TotalRevenueYoYGrowth 2023 -0.82
Recent news
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
2026-07-16 · GlobeNewswire